ABSTRACT
A generic capillary zone electrophoresis method was developed for the analysis of four proton pump inhibitors: omeprazole, pantoprazole, lansoprazole and rabeprazole. During preliminary analysis screening of phosphate buffers at different pH levels was performed, in order to determine the optimum pH domain suitable for the simultaneous determination of all studied compounds. A face centered central composite design was employed for the optimization of separation conditions. The effect of buffer concentration, pH and applied voltage was studied; resolution between peaks and migration time of the last compound were considered as responses. Other factors as system temperature, injection parameters, capillary length, were held constant during the optimization process. The optimized conditions consisted of 40mM phosphate background electrolyte at pH 5.0, +25 kV applied voltage and 20 °C temperature. The migration order of the analytes was as follows: rabeprazole, omeprazole, lansoprazole and pantoprazole. Full resolution of all analytes was achieved within 9 minutes. The method was validated and proved to be suitable in terms of repeatability, sensitivity, linearity, accuracy and robustness. Determinations from commercially available pharmaceutical formulation were performed for omeprazole; good reproducibility and recovery were obtained.
Subject(s)
Research Design , Electrophoresis, Capillary/standards , Proton Pump Inhibitors/analysisABSTRACT
Objetivo: Describir la asociación entre la presencia de alteración cognoscitiva y el consumo de inhibidores de bomba de protones (IBP) en población adulta mayor de Bogotá, Colombia. Métodos: Se analizaron los datos del estudio SABE-Bogotá, que incluyó 2000 personas mayores de 60 años de edad, en una muestra transversal probabilística por conglomerados. La variable de interés fue la alteración en el Mini-Mental State Examination Modificado (MMSE-M), la cual se relacionó con el uso de IBP ajustado por factores como sexo, edad, escolaridad y estado civil. Resultados: La edad promedio fue de 71,17±8,05 años, y el 63,4% eran mujeres. El consumo de IBP se encontró en el 20,7% de la población estudiada, con un tiempo de uso promedio en meses de 74,8±93,76. El 12,6% tenía el MMSE-M alterado, siendo mayor la prevalencia en los consumidores de IBP (25,4% vs. 20,02%; p= 0,049). En el análisis multivariado se encontró una asociación de aumento de riesgo ajustado entre el deterioro cognitivo y el uso de IBP por > 24 meses (OR: 1,90; IC: 1,11-3,24; p = 0,018). Conclusiones: Este estudio muestra una asociación de aumento de riesgo significativa entre deterioro cognitivo consumir IBP durante > 24 meses. Se necesitan más estudios que permitan concluir una relación directa de causalidad.
Objective: The aim of this study was to describe the association between the presence of cognitive impairment and the consumption of proton pump inhibitors (PPI) in community-dwelling older adults from Bogotá, Colombia. Materials and methods: The SABE Bogotá study was analyzed. This study included 2000 people over 60 years, in a cross-seccional sample. The variable of interese was the alteration in the modified Mini-Mental State Examination (MMSE-M). It was related to the use of PPIs. This analysis was adjusted for factors such as sex, age, years of education and marital status. Results: The average age was 71.17 ± 8.05 years, 63.4% were women. The PPIs consumption was found in 20.7%, with an average usage time of 74.8 ± 93.76 months. 12.6% older adults had MMSE-M altered, with a higher prevalence in PPIs consumers (25.4% vs. 20.02%; p: 0.049). In the multivariate analysis, an association of increased risk was found between cognitive deterioration and the use of PPIs for > 24 months (OR: 1.90; IC: 1.11-3.24; p = 0.018). Conclusions: This study shows an association of a significant risk increase between consuming PPIs for > 24 months and having cognitive impairment. More studies are needed to conclude a direct causality relationship.